TABLE 3.
The positivity rates and median antibody titres for the total RBD and ACE2 blocking antibodies for SARS‐CoV‐2 in uninfected and infected vaccine recipients at 3 months following full vaccination
| Vaccine | Antibody type | Number of positive individuals/total number = % positive median (IQR) | P value | |
|---|---|---|---|---|
| Uninfected individuals | Infected individuals | |||
| AZD1222 | RBD‐Abs (Antibody Index) |
297/297 = 100% 13.6 (13.1–14.3) |
28/28 = 100% 13.7 (13.3–14.6) |
0.117 |
| ACE2 blocking‐Abs (% of inhibition) |
66/69 = 95.7% 80.6 (56.4–92.9) |
26/28 = 92.9% 75.1 (56.3–96.0) |
0.87 | |
| Moderna | RBD‐Abs (Antibody Index) |
212/224 = 94.6% 12.7 (11.7–13.3) |
36/40 = 90.0% 12.9 (11.9–13.3) |
0.574 |
| ACE2 blocking‐Abs (% of inhibition) |
223/224 = 99.6% 99.05 (98.4–99.3) |
40/40 = 100% 99.2 (99.1–99.4) |
0.24 | |
| Sinopharm | RBD‐Abs (Antibody Index) |
193/203 = 95.1% 12.4 (6.9–13.4) |
33/33 = 100% 13.5 (13.1–13.8) |
<0.0001 |
| ACE2 blocking‐Abs (% of inhibition) |
67/110 = 60.9% 35.6 (17.7–54.8) |
31/33 = 93.9% 67.0 (44.8–83.2) |
<0.0001 | |
| Sputnik Light (1 dose) | RBD‐Abs (Antibody Index) |
174/184 = 94.6% 13.0 (7.4–13.8) |
33/33 = 100% 13.6 (12.8–14.3) |
0.002 |
| ACE2 blocking‐Abs (% of inhibition) |
37/50 = 74.0% 48.9 (24.9–66.2) |
11/12 = 91.7% 99.3 (89.7–99.4) |
0.001 | |
| Sputnik V (2 doses) | RBD‐Abs (Antibody Index) |
128/128 = 100% 13.6 (13.1–14.1) |
31/31 = 100% 13.6 (13.0–14.6) |
0.984 |
| ACE2 blocking‐Abs (% of inhibition) |
125/128 = 97.7% 88.3 (73.1–97.6) |
31/31 = 100% 99.3 (99.1–99.4) |
<0.0001 | |